Skip to main content
Top

23-11-2017 | Leukemia | Article

Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions

Journal: Supportive Care in Cancer

Authors: Samantha S. F. Lee, Adrienne E. Fulford, Maureen A. Quinn, Jamie Seabrook, Irina Rajakumar

Publisher: Springer Berlin Heidelberg

Abstract

Purpose

The purpose of this study is to evaluate the efficacy and safety of prophylactic oral levofloxacin in acute myeloid leukemia (AML) patients after receiving consolidation chemotherapy to prevent febrile neutropenia.

Methods

We conducted a retrospective chart review of 50 AML patients who were prescribed levofloxacin and 50 AML patients who were not prescribed levofloxacin post-consolidation chemotherapy between June 2006 and August 2013 at a tertiary academic medical center. The primary outcome of this study was to evaluate the effectiveness of levofloxacin in preventing hospital readmission due to febrile neutropenia. Secondary outcomes evaluated the safety of this therapy, including the rate of Clostridium difficile-associated diarrhea (CDAD) within 30 days from discharge of receiving consolidation chemotherapy and rate of fluoroquinolone resistance in positive bacterial cultures.

Results

Hospital readmission due to febrile neutropenia after the first consolidation cycle occurred in 42% of patients prescribed levofloxacin, as compared to 72% that were not prescribed levofloxacin (p = 0.002). This was also significantly reduced when levofloxacin was prescribed after all consolidation cycles (51.4 vs. 67%, p = 0.023). CDAD did not occur in any patient prescribed levofloxacin after the first cycle, compared to one case in those not prescribed levofloxacin. Evaluation of the impact on fluoroquinolone resistance was limited due to a paucity of fluoroquinolone susceptibilities reported.

Conclusions

Prescribing oral levofloxacin post-consolidation chemotherapy in AML patients is associated with a reduction in febrile neutropenia. Further research is required to identify the impact on fluoroquinolone resistance and risk of CDAD.
Literature
1.
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–e93. https://​doi.​org/​10.​1093/​cid/​cir073 CrossRefPubMed
2.
Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffmann KG, Smith C (2016) NCCN clinical practice guidelines in oncology (NCCN guidelines): prevention and treatment of cancer-related infections, version 2.2016. J Natl Compr Cancer Netw 14(7):882–913. https://​doi.​org/​10.​6004/​jnccn.​2016.​0093 CrossRef
3.
Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, del Favero A, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977–987. https://​doi.​org/​10.​1056/​NEJMoa044097 CrossRefPubMed
4.
Simondsen KA, Reed MP, Mably MS, Zhang Y, Longo WL (2013) Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract 19(4):291–297. https://​doi.​org/​10.​1177/​1078155212465215​ CrossRefPubMed
5.
Flowers CR, Seidenfeld J, Bow EJ et al (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Oncol Pract 31(3):794–810
6.
Imran H, Tleyjeh IM, Arndt AS et al (2008) Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 25:53–63
7.
Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20(3):557–560. https://​doi.​org/​10.​1093/​clinids/​20.​3.​557 CrossRefPubMed
8.
Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, Baum H, Marre R (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24(2):111–118. https://​doi.​org/​10.​1007/​s10096-005-1278-x CrossRefPubMed
9.
Martino R, Subira M, Altes A et al (1998) Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. Acta Haematol 99(4):206–211. https://​doi.​org/​10.​1159/​000040840 CrossRefPubMed
10.
Tascini C, Menichetti F, Bozza S, Fedele M, Preziosi R, Allegrucci M, del Favero A, Micozzi A, Martino P, Bistoni F (1999) Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center. Clin Microbiol Infect 5(8):457–461. https://​doi.​org/​10.​1111/​j.​1469-0691.​1999.​tb00175.​x CrossRefPubMed
11.
Chopra T, Chandrasekar P, Salminia H, Heibrun LK, Smith D, Alangaden GJ (2011) Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transpl 25(1):e82–e87. https://​doi.​org/​10.​1111/​j.​1399-0012.​2010.​01331.​x CrossRef